Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Oncology
Oncology · The big question

CREATE Medicines Raises $122M for Next-Generation CAR-T Therapies

STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million

STAT News2 min readAI-assisted summary
Editorial illustration for STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
Editorial illustration

Summary

CREATE Medicines, a biotechnology startup previously known as Myeloid Therapeutics, has secured $122 million in new funding to advance its medical research. Backed by investors including Newpath Partners and ARCH Venture Partners, the company is developing a specialized form of treatment known as CAR-T therapy. This approach typically involves reprogramming a patient's own immune cells to fight disease. However, CREATE Medicines is taking a unique path by utilizing myeloid cells, a specific type of immune agent, to power their therapies.

Originally focused primarily on cancer, the company is designing these myeloid cell therapies with the specific goal of attacking solid tumors. This is a major focus in oncology, as solid tumors are often highly resistant to traditional treatments. Recently, CREATE Medicines also expanded its research pipeline to explore how this same technology might be deployed to treat autoimmune diseases.

While the science is promising, the research is still in its earliest phases. The recent influx of funding is specifically intended to propel the company's first drug candidates through initial human trials. Because of this early-stage status, clinical safety and effectiveness data have not yet been established, and rigorous testing will be required to see how well these therapies perform in actual patients.

Why it matters.

The development of new CAR-T therapies is a highly watched area in medicine because traditional versions have already revolutionized the treatment of certain blood cancers. However, those existing therapies struggle to penetrate and destroy solid tumors, which account for the vast majority of all human cancers. By harnessing myeloid cells instead of the standard immune cells used in older therapies, CREATE Medicines is attempting to solve one of the biggest hurdles in modern oncology. If successful, this approach could bring the powerful benefits of targeted cell therapy to a much larger patient population.

Furthermore, the company's expansion into autoimmune diseases mirrors an exciting shift in the biotechnology industry. Researchers are increasingly discovering that the same tools used to unleash the immune system on cancer might be modified to calm an overactive immune system that is attacking healthy tissue. While these treatments are still years away from routine clinical use, a breakthrough in either cancer or autoimmune care would represent a massive leap forward for patient outcomes and the future of personalized medicine.

From the source

The story in numbers.

Funding raised
$122 million
CAR-T candidates preparing for human trials
1st
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

Colorectal Cancer Prepares to Spread Earlier Than We Thought

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed. By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move. However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Nature Genetics2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗